Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 8/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.41 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12607227 | 0.95 | TNK2 (0.39) | AURKACHEK1TNK2LCKABL1 | |
| SCHEMBL12607233 | 0.94 | AURKA (0.40) | AURKACHEK1TNK2LCKABL1 | |
| SCHEMBL1788636 | 0.94 | TNK2 (0.48) | AURKACHEK1TNK2LCKMERTK | |
| SCHEMBL1788638 | 0.94 | TNK2 (0.48) | AURKACHEK1TNK2LCKMERTK | |
| SCHEMBL1787688 | 0.94 | TNK2 (0.48) | AURKACHEK1TNK2LCKMERTK | |
| SCHEMBL12607234 | 0.94 | AURKA (0.40) | AURKACHEK1TNK2LCKABL1 | |
| SCHEMBL1788637 | 0.94 | TNK2 (0.48) | AURKACHEK1TNK2LCKMERTK | |
| SCHEMBL1787689 | 0.94 | TNK2 (0.48) | AURKACHEK1TNK2LCKMERTK | |
| SCHEMBL14467296 | 0.94 | TNK2 (0.48) | AURKACHEK1TNK2LCKMERTK | |
| SCHEMBL14467485 | 0.91 | AURKA (0.43) | AURKACHEK1TNK2LCKMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | US | disclosed |
| WO-2008131859-A2 | USE OF CYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2007079861-A1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, TK2, TPMT | AURKA 3192/4885CHEK1 291/4885TNK2 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.